Effect of co-administration of alendronate and allan sodium phosphate for the management of osteoporosis
Purpose: To study the therapeutic effect of combination of alendronate and allan sodium phosphate on osteoporosis.
Methods: Patients diagnosed with osteoporosis (100) were randomly assigned to control and study groups (50 subjects/group). The control group received conventional calcium treatment (calcium carbonate D3) after surgery. They consisted of 21 males and 29 females aged 62 to 78 years. The observation group consisted of 22 males and 28 females aged 63 to 77 years (mean age = 68.90 ± 6.43 years), and were treated with sodium alendronate and allan sodium phosphate. Bone mineral density (BMD), bone pain score, clinical effectiveness and levels of calcium, phosphorus, osteocalcin, collagen N-terminal peptide (NTX) and urinary calcium/creatinine were determined using ELISA kits.
Results: After 1 year of treatment, lumbar vertebral and femoral neck BMD significantly increased in both groups. The study group had significantly higher BMD than the controls (p < 0.05). Blood calcium levels increased significantly after 1 year in both groups. The treatment led to a higher level of osteocalcin in the study group than in the control group (p < 0.05). However, the treatment brought about significantly lower NTX level in the study group than in controls.
Conclusion: The results indicate that combined administration of sodium alendronate and allan sodium phosphate is effective for the treatment of osteoporosis.
Keywords: Osteoporosis, Allan sodium phosphate, Alendronate, Apoptosis-related factors, Calcium
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.